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Beta-blocker therapy reduces mortality in patients with coronary artery disease treated with percutaneous revascularization: a meta-analysis of adjusted results Aims The long-term impact of beta blockers on prognosis in patients treated with contemporary therapies for coronary artery disease remains to be defined.
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Methods and results
All observational studies evaluating the impact of beta blockers in patients treated with coronary revascularization and contemporary therapies and adjusted with multivariate analysis were included. All-cause death was the primary endpoint, while Major Adverse Cardiac Events
Introduction
Beta blockers represent a cornerstone for the treatment of coronary artery disease (CAD). Their protective effect is based on the negative inotropic and chronotropic features, which have been tested in a large number of randomized controlled trials, both in patients with myocardial infarction (MI) and in those with stable angina, demonstrating a reduction of adverse cardiovascular events, a relief of symptoms and a reduction of myocardial ischemia. [1] [2] [3] The evidence on their clinical benefits mostly derives from studies in patients not treated with percutaneous coronary interventions (PCI) 4 and with routine medical therapy. Current treatments with drug eluting stents and antithrombotic drugs have improved the natural history of CAD. [5] [6] [7] [8] With these new therapeutic choices, the usefulness and benefit of beta blockers have recently been questioned. Some randomized controlled trials showed an increased risk of in-hospital cardiogenic shock and other analyses did not demonstrate any benefit of early beta blockers administration in the setting of acute phase of acute myocardial infarction (AMI). Moreover, an observational analysis of the REACH registry in patients with and without a prior history of AMI found that beta blockers use was not associated with lower incidence of cardiovascular events. 9, 10 Consequently, we conducted a meta-analysis to evaluate the impact of beta blockers on patients treated with PCI.
Methods
The present research was elaborated according to current guidelines, including the recent Preferred Reporting Items for Systematic reviews and Meta-Analyses amendment to the Quality of Reporting of Meta-analyses statement and recommendations from The Cochrane Collaboration and Meta-analysis of Observational Studies in Epidemiology. [9] [10] [11] [12] [13] Search and inclusion criteria Three authors (F.D.A., M.P., D.E.), independently from each other, searched Pubmed, Medline, Embase, Cochrane and Google Scholar for the following terms: 'myocardial infarction' and 'coronary artery disease' and 'beta blocker'. All articles were independently reviewed, with disagreements resolved by consensus. Inclusion criteria were: human studies, studies evaluating therapy with beta blockers in patients treated with percutaneous revascularization and with contemporary therapies, follow-up longer than 1 year, multivariate adjustment. In the case of duplicate reporting, the article with the largest sample of patients was selected.
Data abstraction
The following data were independently abstracted by three authors (F.D.A., M.P., D.E.) on prespecified electronic forms: authors, journal, year of publication, location of the study group, baseline features (age, risk factors, kind of coronary revascularization and therapy). The corresponding authors of the relevant studies were queried for required quantitative details not in the published articles.
End points
All-cause death was the primary end point, while Major Adverse Cardiac Events (MACE) (a composite end point of all-cause death or MI) and MI were the secondary ones. Meta-regression for all-cause death was performed for age, hypertension, diabetes mellitus and length of follow-up. Subgroup analyses were performed for clinical presentation [acute coronary syndrome (ACS) vs. stable] and for ejection fraction (preserved vs. reduced, defined as equal/more (!) or less (<) than 40%).
Quality study evaluation
The quality of included studies was independently appraised by three reviewers (F.D.A., M.P., D.E.), with disagreements resolved by consensus. Design of the study (multicenter or not), area of enrollement and kind of multivariate analysis were collected. The presence of publication bias was evaluated with the Egger Test.
Statistical analysis
Continuous variables are reported as mean (SD) or median (first and third quartile). Categorical variables are expressed as n (%). Statistical pooling for incidence estimates was performed according to a random-effect model with generic inverse-variance weighting, computing risk estimates with 95% confidence intervals, using RevMan 5.2 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark). Hypothesis testing for superiority was set at the 2-tailed 0.05 level. Hypothesis testing for statistical homogeneity was set at the 2-tailed 0.10 level and based on the Cochran Q test, with I 2 values of 25, 50 and 75% representing mild, moderate and severe heterogeneity, respectively. Meta-regression analysis was performed with random effect with comprehensive meta-analysis.
Results
A total of 1171 records were identified and 26 studies were finally included after screening and full-text assessment (see Appendix web only, Fig. 1 , http://links.lww.-com/JCM/A123). All studies are observational, 16 are prospective and 11 are multicenter (see Appendix, Table  2 , http://links.lww.com/JCM/A123).
A total of 863 335 patients were included. A total of 603 471 (69.9%) underwent PCI for stable angina. Of the total patients 610 476 (70.7%) were on beta-blocker therapy, while 252 859 (29.3%) were not. Most of the patients were men, with a high prevalence of cardiovascular risk factors. Diabetes mellitus was present in 22-41% of the patients (Table 1) . Regarding revascularization, most of them (90% 85-94) were treated with PCI. At 12 months of follow-up aspirin was taken by 95% (90-96), clopidogrel by 69% (68-90), statin by 76% (74-84) and ACE inhibitor/AT1 blocker by 67% (65-80). Table 1 , http://links.lww.com/ JCM/A123), age, hypertension and diabetes mellitus did not impact on this benefit, which was more relevant for those with the longer follow-up (see Appendix Fig. 2 , http://links.lww.com/JCM/A123). When evaluating ejection fraction (Fig. 2) , benefit of beta blockers was reported both in patients with reduced ejection fraction 
Discussion
The current study is the first to appraise the impact of beta blockers in patients treated with coronary revascularization and contemporary therapies. The main results are as follows:
(1) Beta blockers reduce death after 2.5 years of followup (1-5 years). (2) This benefit is irrespective of clinical presentation, being consistent both for the ACS subgroup and stable angina subgroup. (3) The reduction was significant both for patients with preserved ejection fraction and with reduced ejection fraction. (4) This reduction was more evident for patients with longer follow-up.
For decades beta blockers have represented the cornerstone of therapy for CAD, although some limitations about therapeutic adherence in real life and impact in patients treated with revascularization and updated therapies have been recently reported.
14 Beta blockers by prolonging the diastolic filling time and decreasing vascular resistance in nonischemic areas increase coronary perfusion of the ischemic areas and improves the contractility of viable but hibernating myocardial regions. Moreover, the prevention of myocardial wall stress might also contribute to the prevention of myocardial rupture. 15, 16 The first demonstration of reduction of mortality offered by propranol dates back to 1965, and since then a large number of randomized controlled trials and meta-analyses have confirmed this benefit. 17, 18 It should be remembered, however, that these studies have been performed before the introduction of reperfusion and revascularization strategies, which may potentially offset this benefit.
A few randomized clinical trials have been conducted in the era where PCI and dual antiplatelet therapy represent the standard of care, although these studies have important limitations.
The first study performed by Hanada et al.
19 found no effect of intravenous beta blockers on the risk of inhospital or long-term cardiac events, nor on arrhythmias during the first 24 h. However, the small sample size of this trial might have resulted in insufficient power to detect significant differences in events. In the METO-CARD-CNIC trial 20 there were fewer numerical MACE (defined as the composite of death, readmission due to Heart Failure (HF), recurrent MI, and malignant ventricular arrhythmias) after prereperfusion intravenous metoprolol administration, but without reaching a statistical significance. The reason for this result depends on the small sample size (n ¼ 270). Moreover, all patients presented with anterior ST Elevation Myocardial Infarction (STEMI), whose myocardial involvement might be potentially greater than other types of infarction.
In 2016, the EARLY-BAMI trial 21 evaluated the effect of early, prehospital, prereperfusion administration of intravenous metoprolol on MI size in patients with STEMI. The investigators reported no difference in MI size between the two groups. It is important to state that this study only reported the short-term effects.
Diagnostic evaluation of ischemic disease has never been as deep as nowadays. Assessment of functional significance Long-term risk of all-cause death according to beta-blocker therapy for patients with preserved or reduced ejection fraction.
of coronary disease by fractional flow reserve is now possible with noninvasive computed tomography allowing better risk stratification and choice of therapeutic approach also in stable patients. 22 New anatomical and functional analysis with cardiac magnetic resonance and its capability to detect possible complications of ACS and PCI open even more space for revascularization therapy. 23 The number of PCI performed in Italy has steadily grown over the last decade, especially for patients with acute MI 24 and with an increasing trend in early invasive approach also in the elderly patients. 25 Moreover, coronary revascularization has shown to improve prognosis not only in patients with ACS, but also in stable patients, in particular those with evidence of moderate or severe ischemia, as can be detected by myocardial perfusion scintigraphy. 26, 27 Finally, adherence to beta blockers in real life was described as low, being about 58% after 5 years of follow-up, which is lower than other drugs like statins, probably due to their side effects. 28 Consequently, especially after the analysis of the REACH registry, usefulness of beta-blocker therapy has been largely questioned. 4, 10 In our study, beta blockers do not reduce MACE in patients with ACS; a possible explanation for our result is intrinsic to the characteristics of the ACS population of our study. In fact, our patients have a median ejection fraction of 52.6% (Table 1 ) and different studies demonstrate evidence of efficacy in reducing MACE and mortality only in patients with ejection fraction 40% or less. [29] [30] [31] [32] [33] In the present article, beta blockers reduced mortality in CAD patients treated with PCI, irrespective of clinical presentation. This benefit was probably related to the decrease in sympathetic activation, which represents a common pathway for stable and not stable CAD. 34, 35 This activation, especially at mid-term and long-term follow-up, decreases the ventricular fibrillation threshold, resulting in increased propensity for sudden cardiac death and ventricular arrhythmias. For instance, in a recent observational study of Di Marco on chronic total occlusion, sympathetic activation was reported as an independent predictor of ventricular arrhythmias and sudden cardiac death. 36 Furthermore, there is evidence that the absence of betablocker therapy is one of the most important predictors of appropriate implantable cardioverter defibrillator interventions, [37] [38] [39] [40] [41] stressing the protective role of beta blockers. Moreover, inhibition of sympathetic activation reduces ventricular remodeling leading to prevention of HF. 42, 43 Consequently, beta blockers reduce mortality through the prevention or reduction of negative contractile and electrical remodeling.
Moreover, there is increasing evidence in the literature of the prognostic role of microcirculation in patients with MI. Recent studies demonstrated that the index of microcirculatory resistance and the hyperemic microvascular resistances are related to the microcirculation status and their assessment showed a prognostic value. 44 In this setting, beta blockers can be protective in that subset of patients with poor outcome, in which optimal recanalization of the epicardial vessels did not result in an actual improvement in myocardial perfusion due to damage of the microcirculatory bed.
The increase in benefit using beta blockers at long-term follow-up for a reduction in death may impact the management of patients, as their protective role seems irrespective of ejection fraction. It should be remembered that about 20% of subsequent coronary adverse events that occur after a first episode of ACS are related to nonculprit plaque, usually not treated with revascularization, as described recently in the PROSPECT study. 45 Moreover, plaque stabilization or regression 46 has been related to a decrease in subsequent MI but not in death. Indeed, benefit of beta blockers may be more important at longer follow-up by preventing and reducing ischemic and arrhythmic events related to plaque progression or abrupt instabilization of coronary atherosclerosis. 7 Similarly, the benefit of beta blockers was independent from ejection fraction. Although their protective role in patients with HF has largely been described, irrespectively of HF cause, 47 the benefit in patients with preserved left ventricle function has been questioned. In the present analysis, beta blockers reduced mortality both for patients with reduced or preserved ejection fraction, due to their protective effect on ventricular arrhythmias and further ischemic events.
Secondary prevention in patients with CAD has shown increasing evidence and with the growing population of ACS survivors comprehensive risk factor management can improve survival, reduce recurrence and the need for interventional procedures and improve the quality of life of these patients.
There is an improvement in the use of the current guidelines recommending pharmacological therapy for secondary prevention in European countries such as Portugal, where a recent study showing that the vast majority of patients after an ACS are currently receiving beta blockers, antiplatelet therapy, statins and ACE inhibitors, and there is a trend toward earlier start of therapy before discharge. 48 Complementary to behavioral changes a fixed dose combination or a so-called polypill containing two or more drugs addressed at controlling various risk factors might reduce costs and improve patient accessibility and adherence to treatment. 49 The present analysis stressed the importance of betablocker therapy also in the PCI era. Verapamil may represent a potential alternative, being noninferior to atenolol in a recent RCT, although this was a prespecified subanalysis. 40 On the other hand, ivabradine, although promising in patients with HF, recently failed to demonstrate any benefit for stable CAD. Finally, as demonstrated by the Egger Test publication bias was low (see Appendix, Fig. 6 , http://links.lww.com/JCM/A123).
Limitations
Our article has some limitations. It is a meta-analysis built on studies that present heterogeneity and it does not derive from randomized controlled trials. All included studies were observational with all potential limitations. Some of the studies were also retrospective with potential adjudication and attrition bias. Moreover, these studies did not have data on different kinds of beta-blocker therapy and on when it was started or discontinued. Finally, publication bias was low, as demonstrated by nonsignificant Egger Test (p. 0.67, see Appendix, Fig. 6 , http://links.lww.com/JCM/A123).
